# Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

> **NCT06818097** · — · COMPLETED · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 68 (actual)

## Conditions studied

- Advanced HCC
- Systemic Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Efficacy and Safety

## Interventions

- **DRUG:** TKI
- **DRUG:** anti PD-1
- **DRUG:** XELOX chemotherapy

## Key facts

- **NCT ID:** NCT06818097
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818097, "Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06818097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*